CignaCIRevenue: is the business selling more than it used to?
$274.9B+11% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $274.9B in 2025, compounding +15% a year since 2022 and the pace is picking up. The last twelve months (+8%) ran below that pace, so growth is slowing. The trailing twelve months are already running at $282.4B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCINet income: how much of that revenue becomes profit?
$6.0B+73% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $6.0B in 2025, compounding -4% a year over three years. Earnings per share moved +32% over the last twelve months. Trailing twelve-month profit stands at $6.4B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIHow fast is it growing, year by year?
+11.2%revenue growth, FY 2025
→Revenue grew +11% in 2025 against a five-year average of +12%. Earnings grew faster (+73%), so each new dollar of sales is arriving more profitably.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIRevenue per share: is your slice growing as fast as the company?
$1023.60revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $1023.60 in 2025, compounding +21% a year against +15% for CI as a whole. Buybacks added roughly 6.0 points to your per-share result.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin has held near 3% since 2022. After everything, 2 cents of each sales dollar reaches net profit. CI doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of 15% and ROCE of 9% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIWhat has the market paid for CI over time?
11.8xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 11.8x earnings, the market is paying 23% less than CI's own 10-year median of 15.3x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCICould it handle its debt if things went wrong?
→Debt of $31.9B sits against $6.3B of cash, or 0.7x shareholders' equity. Earnings cover interest 7.0 times - adequate, with less room than it looks in a downturn.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIIs the company's own capital growing?
→The company's own capital shrank from $46.2B in 2023 to $42.6B (-8%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIHow much goes back, and how much leaks out as stock comp?
→Shareholders received $3.6B in buybacks and $1.6B in dividends in 2025. Stock compensation issued $291M of new shares in the same year, offsetting 6% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIHow fast is your ownership being diluted - or concentrated?
→The share count shrank 5.2% in 2025, averaging 5.0% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIIs the dividend cheque growing?
→The dividend per share reached $6.00 in 2025, compounding +171% a year since 2020.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCICan it afford the dividend?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The dividend consumed 27% of profit and 17% of free cash flow in 2025. That leaves room to keep paying through a weak year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIDoes CI earn more on its capital than that capital costs?
→CI earns 14.3% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 15.2% in 2022, so the trend is down, though the pace has cooled.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCICI has issued or retired shares - did shareholders end up better off?
→CI issued +3% more shares from 2016 to 2025, but revenue per share still rose +567%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
CignaCIAre the people running it buying or selling?
→Insiders bought $999,916 and sold $77M on the open market, a net sale of $76M. A further 42 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30